Charged Alpha Stock Encyclopedia

Etsy, Inc. (ETSY) Q2 2026 — Q2 GAAP diluted EPS $(0.36) vs a ~$0.75 bar - while revenue BEAT at $668.3M vs $646.1M est. Continuing-operations diluted EPS was $0.98, a 31% beat. The entire gap is Depop, sold to eBay on July 30 and booked as a discontinued operation: $(161.0)M, or $(1.34) a diluted share. GMS $2.6B +7.5%, take rate 25.9%, adjusted EBITDA $195.4M at a 29.2% margin. FY26 margin guidance RAISED to 29-30%. New $2B buyback. Stock -4.19% to $82.26 on the print.

Etsy 'missed' by $1.11 and beat on revenue in the same release. Both facts are true, and they are not in tension: the $(0.36) headline is total diluted EPS including discontinued operations, while the ~$0.75 bar was a continuing-operations estimate. Continuing operations earned $0.98. Depop - sold to eBay on July 30 - cost $160,989 thousand, which over 119,961 thousand diluted shares is exactly $(1.34). $0.98 minus $1.34 is $(0.36). And the Depop loss was driven by $170.2M of Q2 marketing against $21.1M a year ago, spending Etsy's own letter says was 'recovered through purchase price adjustments on the closing date' - eBay reimbursed it via $200M of adjustments at the $1.4B close. Next quarter GAAP lies the other way: an estimated $840M gain on an asset Etsy bought for $1.625B and sold for $1.4B.

THE CALL: BUY (3/5, THE MISS IS A DEPOP ARTIFACT. THE GROWTH IS PRICE-LED) — base-case value ~$105.0 vs ~$82.26 today.

KEY METRICS:

- CALL: BUY 3/5, fair value ~$105 vs the $82.26 tape (+28%). Street: 45 analysts, $75 avg target - BELOW the price. We DIFFER.

- Continuing-ops diluted EPS $0.98 vs a ~$0.75 bar. The $(0.36) headline is Depop: $(161.0)M of discontinued ops = $(1.34)/share.

- Rev $668.3M vs $646.1M est. GMS $2.6B +7.5%. Take rate 25.9%. Adj EBITDA $195.4M, 29.2%. FY margin guide RAISED to 29-30%.

What to watch: UP: trailing-twelve-month active buyers turning positive, purchase frequency turning positive, or the new $2B authorization actually being spent near $82. BEAR: take rate stalling below 26%, a Q4 guide with GMS growth back under 4%, or seller churn showing up in active listings.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Talen Energy Corporation (TLN) Q2 2026 — Q2 GAAP EPS $(2.00) vs a $3.21 bar; revenue $747M vs $832.8M est - but revenue INCLUDES a $(212)M non-cash derivative mark. Ex-mark revenue $959M, a 15% BEAT. Adjusted EBITDA $374M vs $90M LY; Adjusted FCF $212M vs $(78)M. 2026 guidance RAISED to $2,025-$2,225M EBITDA and $1,200-$1,350M FCF. Stock +2.6% to $338.31 on the print, 24% off its October high.

Talen 'missed' by $5.21 and raised guidance on the same page. Both the EPS miss and the revenue miss are manufactured by one non-cash line: a $(212)M unrealized mark-to-market loss on power hedges, booked INSIDE the revenue line. Energy plus capacity revenue was $959M against a $832.8M bar. Add the $211M mark, $71M of stock comp and $28M of deal costs back to the $(129)M pre-tax loss and you get $184M of adjusted pre-tax income - $2.86 to $3.17 a share against a $3.12-$3.21 bar. The hedges are underwater because forward power prices went UP, which is exactly what makes the 70% of 2028 that is unhedged worth more.

THE CALL: BUY (3/5, THE MISS IS AN ARTIFACT. THE LEVERAGE IS NOT) — base-case value ~$385.0 vs ~$338.31 today.

KEY METRICS:

- CALL: BUY 3/5, fair value ~$385 vs the $338.31 tape (+14%). Street: 13 analysts, 11 Buy / 2 Hold / 0 Sell, $464.14 avg. We AGREE on direction, DIFFER by 17% on the number.

- Adj EBITDA $374M vs $90M. Adj FCF $212M. Generation 14.1 TWh vs 7.3. Bridge: +$211M derivative mark, +$214M interest, -$134M NDT gain.

- EV $25,375M = 11.9x 2026E EBITDA, 8.9x our 2028E $2,850M. Net debt $9,171M = 4.3x vs a <3.5x target. 2028 only ~30% hedged: $45M of margin per $1/MWh.

What to watch: UP: a new data-centre PPA out of the ~4 GW pipeline, 2028 hedges rolling on above $66/MWh, or net leverage printing below 3.5x. BEAR: PJM forwards breaking under $60/MWh, the buyback pausing to protect the rating, or Fitch turning its negative outlook into a downgrade.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Pfizer Inc. (PFE) Q2 2026 — Q2 revenue $15,034M UP 3% reported but just 1% operationally, against a $14.55B Street bar. Adjusted EPS $0.77 beat a $0.68 consensus by 13% - and came in BELOW the $0.78 earned a year earlier. GAAP was a LOSS of $(0.04) on $4.3B of intangible impairments. FY26 revenue guidance raised $500M at the midpoint to $60.5-$62.5B; adjusted EPS guidance REAFFIRMED at $2.80-$3.00. Stock +3.9% since the print, at $25.995.

Pfizer beat by 13% and lost money. Adjusted EPS of $0.77 cleared a $0.68 bar - but the company earned $0.78 in the same quarter of 2025, and first-half adjusted EPS is $1.52 against $1.69, down 10%. On a GAAP basis Q2 was a $(248)M net loss, because Pfizer wrote off $4.3B of intangibles: $3.8B against the failed Phase 3 of sigvotatug vedotin, the first new ADC out of the $43B Seagen deal, and $525M retiring Oxbryta. None of it touches the adjusted number. Meanwhile $22,860M of revenue - 37% of the guide - carries a patent expiry date, starting with Eliquis in 2028.

THE CALL: AVOID (3/5, A NINE-TIMES MULTIPLE ON EARNINGS THAT ARE NOT CASH) — base-case value ~$17.0 vs ~$25.995 today.

KEY METRICS:

- CALL: AVOID 3/5, fair value ~$17 vs the $25.995 tape (-35%). Street: 39 analysts, 15 Buy / 23 Hold / 1 Sell, $26.88 avg - which itself implies only +3%. We DIFFER on size, not direction.

- Q2 revenue $15,034M (+1% operational). Adjusted EPS $0.77 vs a $0.68 bar and $0.78 a year ago. GAAP $(0.04). $4.3B of impairments: $3.8B sigvotatug vedotin, $525M Oxbryta.

- 8.96x guided EPS but 18.2x EV/free cash flow. TTM FCF $10,986M vs a $9,838M dividend. LOE-exposed revenue $22,860M = 37% of guide. Tangible book NEGATIVE $33.3B.

What to watch: UP: berobenatide Phase 3 data competitive with Lilly, free cash flow sustaining above $12B, or - counter-intuitively - a dividend cut that redirects $4-5B a year into the pipeline. BEAR: Eliquis U.S. erosion arriving before 2028, another impairment on a Seagen asset, or the payout ratio going back above 100% of free cash flow.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Fox Corporation (FOXA) Q4 FY2026 — Q4 revenue $4,212M UP 28% vs a $3,643M Street bar. Advertising $1,916M UP 78% on the FIFA Men's World Cup. Adjusted EBITDA $1,195M UP 27%. Adjusted EPS $1.79 vs $1.44. Full year: record revenue $17,126M and record adjusted EBITDA $3,906M. Stock +5.1% to $61.67 - still 19% below its January high.

Fox closed fiscal 2026 with record revenue of $17.13B and record adjusted EBITDA of $3.91B, and a June quarter that grew 28% on the FIFA Men's World Cup. Adjusted EPS $1.79 against a $1.44 bar. Yet the stock sits 19% below January. The reason is not the quarter: on June 15 Fox announced it was buying Roku for $160 a share, and FOXA fell 16.8% in one session. Full-year GAAP EPS fell to $3.84 from $4.91 - but that is a $1.2B Flutter mark, not the business. Adjusted EPS rose to $5.42.

THE CALL: BUY (3/5, CHEAP ENOUGH TO SURVIVE ITS OWN DEAL) — base-case value ~$70.0 vs ~$61.67 today.

KEY METRICS:

- CALL: BUY 3/5, fair value ~$70 vs the $61.67 tape (+13.5%). Street: 48 analysts, 24 Buy / 24 Hold / 0 Sell, $68 average - we ALIGN. Standalone $85, pro-forma $66, bear $52.

- Q4 revenue $4,212M (+28%), adjusted EBITDA $1,195M (+27%), adjusted EPS $1.79 vs a $1.44 bar. FY26 revenue $17,126M and adjusted EBITDA $3,906M, both records.

- EV $26,974M = 6.9x adjusted EBITDA; 11.4x adjusted EPS. Reverse-DCF implies -0.2% growth forever. Roku costs $14.2B cash plus 143.8M shares - 34% dilution.

What to watch: UP: a Roku close with synergies raised above $400M, FY27 free cash flow recovering toward $2.5B as World Cup working capital unwinds, or a move on the FanDuel option. BEAR: cable distribution revenue that stops growing, the buyback pausing to fund the deal, or pro-forma leverage above 3.5x.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

MACOM Technology Solutions Holdings, Inc. (MTSI) Q3 FY2026 — Revenue $342.2M UP 35.8% and UP 18.4% sequentially - above the Street AND above MACOM's own $331-339M guide. Adjusted EPS $1.40 vs $1.35. Adjusted gross margin 59.7%, adjusted operating margin 31.5%. Then the guide: fiscal Q4 revenue $415-425M vs a $364.1M consensus and adjusted EPS $1.97-$2.03 vs $1.49. Stock +11.0% to $292.54.

MACOM beat the June quarter by five cents - $1.40 adjusted against $1.35. Then it guided September to $1.97-$2.03 against a $1.49 Street bar, on $415-425M of revenue against $364M. The guide, not the print, is the story, and it is the best MACOM has ever given. But GAAP EPS of $1.28 is one-third a $41.5M non-cash mark on MACOM's new IQE plc stake, and adjusted EPS adds back $24.5M of stock comp. At $292.54 the price already assumes ~20% free-cash-flow growth for a decade.

THE CALL: AVOID (3/5, A SUPERB QUARTER AT OUR BULL-CASE PRICE) — base-case value ~$225.0 vs ~$292.54 today.

KEY METRICS:

- CALL: AVOID 3/5, fair value ~$225 vs the $292.54 tape (-23%) - and $75 BELOW the Street's $300 LOW target. Panel: 24 analysts, 15 Buy / 7 Hold / 2 Sell, $403.86 average (+38%); an independent 14-analyst panel says $400.92, same bounds. Base $225: FY27 revenue $2,100M, adjusted operating income $807M, less $120M stock comp, 12% cash tax, $158M capex, 32% growth fading to 5%, 10.0% discount. Bull $305, bear $115.

- THE GUIDE IS THE STORY, NOT THE PRINT. Fiscal Q3 revenue $342.237M beat the Street's $335.5M by 2.0% and adjusted EPS $1.40 beat $1.35 by five cents - both also above MACOM's OWN May guide of $331-339M and $1.31-$1.37. Then fiscal Q4: revenue $415-425M against a $364.1M consensus (+15%) and adjusted EPS $1.97-$2.03 against $1.49 (+34%). The midpoint is +22.7% sequential and +60.8% on last September's $261.2M.

- GAAP EPS OF $1.28 IS ONE-THIRD A NON-CASH MARK. Other income carries a $41.543M 'gain on investment fair value' - the mark on the IQE plc stake MACOM subscribed for on April 27, 2026 (GBP 30M of new ordinary shares, under 12% of IQE, plus GBP 15M of convertible loan notes), carried at $102.132M in long-term investments. That is a third of the $123.850M of pre-tax income. MACOM's adjusted $1.40 correctly excludes it.

- THE OPERATING LEVERAGE IS REAL - AND SO IS THE STOCK COMP. Revenue +35.8% while adjusted opex grew 18.2% ($96.533M vs $81.682M, 28.2% of revenue from 32.4%). Adjusted EBITDA $116.735M, a 34.1% margin from 27.9%. The Q4 guide implies ~$96M of adjusted opex - flat - a 64% incremental margin. But adjusted EPS adds back $24.511M of stock comp (7.2% of revenue): expense it and $1.40 is ~$1.10 and the $2.00 guide is ~$1.69.

- WHAT $292.54 REQUIRES. EV $22,899M (79.5M diluted shares, $358M net cash) = 19.7x trailing revenue, 13.6x the September guide annualised, 10.9x our FY27 revenue and 26.9x our FY27 adjusted EBITDA. Run the owner-earnings model backwards: $292.54 needs ~20% free-cash-flow growth for ten straight years, roughly $12.9B of revenue by FY2037 - about ten times the $1.32B MACOM will do this year. Our bull case is $305.

- MIX AND CONCENTRATION (Q2 FY26 10-Q, the last disclosed): Industrial & Defense $120.652M (41.8%, +22.4%), Data Center $98.188M (34.0%, +36.0%), Telecom $70.115M (24.3%, +7.6%). Geography: China and Hong Kong $99.179M - 34.3% of revenue, +55% year on year. Top ten customers were 57% of revenue. Balance sheet: $663.0M cash and short-term investments, $340.5M short-term debt, 9M free cash flow ~$145.8M.

What to watch: UP: a December quarter holding $420M or better, a Data Center line above $180M, or adjusted operating margin near 40%. BEAR: a December guide below the September level, inventories outgrowing revenue, or export-control action touching the 34.3% of revenue billed into China.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Insmed Incorporated (INSM) Q2 2026 — Revenue $425.5M UP 296% vs a ~$393M bar. BRINSUPRI $309.2M in launch quarter four, UP 49% sequentially. GAAP EPS -$0.06 vs a -$0.69 bar - but 88% of that result is a $99.8M NON-CASH gain on an earnout settled in Insmed's own shares. Ex-mark EPS is -$0.52, a 17-cent beat. FY26 BRINSUPRI guidance RAISED to $1.25-$1.40B from 'at least $1B'. Stock +32.0% to $130.73.

Insmed reported a net loss of six cents a share against a sixty-nine cent bar. Inside operating expenses sits a $99.8M non-cash GAIN on an earnout the 10-Q says is settled in Insmed's OWN shares. INSM fell 34.8% during the quarter - so the earnout got cheaper, and that is the beat. Strip it out and EPS is -$0.52: a 17-cent beat, not 63. The revenue beat IS real, and it is why the stock is up 32%. But at $130.73 the price already assumes the company's entire >$14B peak-sales ambition.

THE CALL: AVOID (3/5, A REAL LAUNCH AT A PRICE THAT NEEDS EVERYTHING) — base-case value ~$91.0 vs ~$130.73 today.

KEY METRICS:

- CALL: AVOID 3/5, fair value ~$91 vs the $130.73 tape (-30%) - and 43% BELOW the Street's $161 LOW target. Panel: 35 analysts, 33 Buy / 1 Hold / 1 Sell, $199.82 average (+53%). Base $91: risk-adjusted peak revenue $9.9B in 2034 (BRINSUPRI $6.0B, ARIKAYCE $0.9B, TPIP $2.5B against a >$6B claim), FCF at 26% of sales, 10.5% discount, 2.5% terminal, +$264M net cash, 225.0M shares. Bull $150, bear $32. Backwards: $130.73 needs ~$14.3B of peak revenue.

- THE 63-CENT EPS BEAT IS 88% NON-CASH. GAAP EPS printed -$0.06 against a -$0.69 bar, but total operating expenses of $427.034M include a NEGATIVE $99.760M 'change in fair value of contingent consideration liabilities'. Add it back: operating loss -$101.3M not -$1.5M, net loss -$113.0M, EPS -$0.52. The real comparable beat is 17 cents. And it reverses - at $130.73 that same earnout is worth ~$182.3M against $149.2M, a ~$33M Q3 charge.

- WHY: THE EARNOUT IS SETTLED IN INSMED'S OWN SHARES. 10-Q Note 3 - the Aug-2021 Motus Biosciences / AlgaeneX earnout is up to 4,610,838 + 368,867 = 4,979,705 shares, 'settled in shares of the Company's common stock. As such, there is no discount rate applied', at a 28% weighted-average probability. 4,979,705 x 28% x $106.62 (the 6/30/26 close) = $148.7M; the filing says $149.2M. INSM fell 34.8% in the quarter. That fall IS the gain.

- THE REVENUE BEAT IS REAL. Product revenue $425.486M against ~$393M expected, +296% YoY. BRINSUPRI $309.2M in launch quarter four, +49% sequentially against a ~$285M whisper (US $308.6M, international $0.6M). ARIKAYCE $116.3M, +8% - but US ARIKAYCE only +2%. Gross margin 84.2% from 73.9%. FY26 BRINSUPRI guidance RAISED to $1.25-$1.40B from 'at least $1B'; ARIKAYCE reiterated $450-470M. The 8-K was accepted 7:00am ET - a BMO print.

- THE LEVERAGE IS REAL, THE PRICE IS NOT. Ex-mark operating loss -$101.3M against -$312.9M; six-month operating cash burn -$311.6M from -$467.7M while revenue tripled; we model a ~-$22M Q4 operating loss. Cash and securities $1,160M against $896M of obligations = +$264M net. But EV $28.3B is 24.9x TTM revenue, 15.8x the 2026 guide and 2.0x the company's own >$14B peak claim - $6B of which is TPIP, with 4 Phase 3s and zero readouts.

- PRIMARY SOURCES (Insmed, SEC CIK 0001104506): 8-K accession 0001140361-26-031502, Ex-99.1, accepted 2026-08-06 07:00:41 ET; 10-Q accession 0001104506-26-000041, accepted 06:59:58 ET. Quarterly revenue from SEC XBRL companyconcept.

What to watch: UP: a positive PALM-PAH or PALM-ILD Phase 3 readout, BRINSUPRI clearing $400M in a single quarter, or a Japanese approval with real pricing. BEAR: BRINSUPRI sequential growth under 15%, a large equity raise into this 32% move, or a US ARIKAYCE line that keeps printing 2% growth while international carries it.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Warner Bros. Discovery, Inc. (WBD) Q2 2026 — Revenue $8,717M DOWN 12% ex-FX. Adjusted EBITDA $1,879M DOWN 6% ex-FX. Free cash flow $572M after ~$350M of deal costs. Streaming's first-ever $3B quarter, Adjusted EBITDA +63% ex-FX to $512M. Net debt $29.7B at 3.4x. GAAP EPS $0.06 vs a -$0.13 bar - but that is a $433M tax benefit on a $271M pre-tax loss. Stock +1.98% to $26.49 on a pre-market print.

Warner Bros. Discovery is under a signed, shareholder-approved, all-cash merger at $31.00 a share from Paramount Skydance - and the stock is $26.49, a 17% discount. That gap is not a view on earnings. In July, twelve state attorneys general and the Writers Guild sued in the Northern District of California to block the deal under Section 7 of the Clayton Act, and nobody can close until five days after a merits ruling or June 1, 2027. The quarter itself was fine: Adjusted EBITDA $1,879M, Streaming's first $3B revenue quarter with EBITDA up 63% ex-FX, and $15B of bridge debt refinanced. None of it matters much next to the court date.

THE CALL: HOLD (3/5, YOU ARE UNDERWRITING A TRIAL, NOT A MEDIA COMPANY) — base-case value ~$27.0 vs ~$26.485 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value ~$27 vs the $26.49 tape. Street Hold, ~$30 avg (32 analysts).

- DEAL: Paramount Skydance $31.00 CASH plus a ticking fee. Closes $31.68, breaks $17.50.

- Q2: revenue $8,717M -12% ex-FX. Adjusted EBITDA $1,879M -6%. Free cash flow $572M.

- The $0.06 EPS is a $433M TAX BENEFIT on a $271M pre-tax LOSS. Use EBITDA, not GAAP.

- 12 state AGs and the Writers Guild sue to block. No close before Jun 1 2027; outside date Jun 4.

What to watch: UP: a merits ruling for the defendants, a settlement with the twelve state attorneys general, or a firm trial date comfortably before the June 2027 outside date. BEAR: an injunction, an appeal that pushes past June 4 2027, or any sign the parties are renegotiating the $31.00 price downward.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Block, Inc. (XYZ) Q2 2026 — Gross profit $3,166M UP 25% vs its own $3.04B guide. Adjusted EPS $1.02 UP 65% vs an $0.871 bar. GAAP EPS $0.15 DOWN 83%. Record 27% adjusted operating margin. FY26 guide RAISED to $12.51B and $4.02 - but the implied second half went up only $54M of gross profit and $6M of operating income. Stock -4.75% to $80.20.

Block (formerly Square, ticker SQ, now XYZ) beat and raised, and the stock fell 4.75%. Here is why: the full-year gross profit guide went up $180M and $126M of that was the quarter already banked, so the entire second half rose $54M - 0.85%. On adjusted operating income the raise was $130M against a $124M beat: the back half moved $6M. And gross profit growth goes 27%, 25%, a guided 18%, and an implied 15% in Q4 - the Q3 guide of $3.13B is BELOW what Q2 just printed. The record 27% margin came from a workforce cut of more than 40%.

THE CALL: HOLD (3/5, THE MARKET GOT THIS ONE RIGHT) — base-case value ~$82.0 vs ~$80.2 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value ~$82 vs the $80.20 close. Street $95.08 avg (35 analysts). Bull $113, bear $45.

- GROSS PROFIT $3,166M +25%. Cash App $1,973M +31%, Square $1,160M +13%. Adjusted EPS $1.02 vs an $0.871 bar.

- THE RAISE IS THE QUARTER: FY gross profit +$180M, $126M already banked. Implied H2 +$54M. Operating income H2 +$6M.

- GROWTH DECELERATES 27% to 25% to a guided 18% to an implied 15%. Q3 guide $3.13B is below Q2's $3,166M print.

- BITCOIN IS 29% OF REVENUE AND 2.3% OF GROSS PROFIT ($1,894M revenue, $72M profit). DOJ accrual $526M, may exceed.

What to watch: UP: Cash App monthly actives back above 60M, a September quarter that beats the $3.13B bar without giving it back, or a DOJ settlement inside the $526M accrued. BEAR: transaction and loan losses above 20% of gross profit, actives below 59M, or a 2027 guide with gross profit growth starting with a one.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Motorola Solutions, Inc. (MSI) Q2 2026 — Sales $3,133M UP 13% vs a ~$3,031M bar. Non-GAAP EPS $4.41 UP 24% vs a $3.85 bar - and $0.53 above the TOP of the company's own May guide of $3.82-$3.88. GAAP EPS $3.33 UP 10%. Record Q2 backlog $15.6B UP 11%. FY26 guide RAISED for the third time to ~$12.975B and $17.62-$17.72. Stock +7.6% to $471.25.

Motorola Solutions grew revenue $368M this quarter. $243M of it was acquisitions and $35M was currency - the release says both figures by name. The business that already existed a year ago contributed $90M, or 3.3%. The company's own organic line is +5%, not the +13% headline, and +2% over six months. Meanwhile $0.25 of the $4.41 non-GAAP EPS was a $60M pre-tax IEEPA tariff refund. The beat and the third guidance raise are real. The growth rate underneath them is five percent.

THE CALL: HOLD (3/5, A GREAT BUSINESS AT A FULL PRICE) — base-case value ~$416.0 vs ~$471.25 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value ~$416 vs the $471.25 close (-11.8%) - BELOW the Street's $470 LOW target. The panel is 34 analysts: 24 Buy, 6 Hold, 4 Sell, $512.17 average (+8.7%). Base $416 (TTM FCF $3,050M growing 9% then 5%, 8.2% discount, 2.5% terminal, less $7,707M net debt and $1,500M for D-Fend, over 168.0M shares); bull $557; bear $328. Run it backwards: $471.25 needs free cash flow to compound 11.7% a year for five straight years. Our base already gives it 9%.

- THE BEAT WAS REAL, AND AGAINST ITS OWN RAISED BAR. On May 7 Motorola guided Q2 to ~8.5% revenue growth and non-GAAP EPS of $3.82-$3.88. It printed +13.3% and $4.41 - fifty-three cents above the TOP of its own range. The full-year guide has gone $16.70-$16.85, then $16.87-$16.99, now $17.62-$17.72: three raises in a row, with consensus of $16.96 sitting on the May midpoint. Revenue guide went ~$12.8B to ~$12.975B. This is NOT a beat against a cut bar.

- STRIP THE ACQUISITIONS AND 13% BECOMES 5%. Sales grew $368M, from $2,765M to $3,133M. The release states revenue from acquisitions was $243M and FX tailwinds were $35M - leaving $90M, or +3.3%, from the business that already existed. The company's own Non-GAAP-5 organic line is $2,890M vs $2,765M, +5%. Over six months organic revenue was $5,382M vs $5,290M: +2%. Segment margins did go UP - P&SI 31.4% from 26.7%, S&S 35.3% from 33.8%.

- A QUARTER OF THE BEAT WAS A TARIFF REFUND. Footnote 2: the $4.41 and the 32.9% margin are inclusive of a $60M pre-tax IEEPA refund - $0.25 a share and 190bps. Ex-IEEPA the quarter is $4.16 (still +$0.31 vs the bar) at a 31.0% margin (+140bps). And the FY midpoint rose $0.74 ($16.93 to $17.67) while Q2 alone beat by $0.56 - the entire back half went up $0.18. Q3 revenue is guided +8% after a +13.3% quarter; Q3 EPS midpoint $4.415 is flat vs $4.41.

- VALUATION AND WHAT Q4 HAS TO DO. EV ~$86.6B is 7.1x TTM revenue of $12,236M, 28.4x TTM FCF of $3,050M, 26.7x the guided $17.67, and 24.4x a marked-up ~$19.35 for 2027. FCF has compounded 19%/yr: $1,790M, $2,130M, $2,570M, $3,050M. Backlog is a record $15.6B, +11%. But H1 revenue was $5,848M and a +8% Q3 is ~$3,250M, so Q4 must hit ~$3,878M, +14.7%, to reach $12.975B. Inventory is $1,333M from $983M on memory-cost inflation.

What to watch: UP: organic revenue growth back above 8%, a Q4 that actually delivers the implied ~$3,878M, or a 2027 guide that absorbs memory costs without a margin cut. BEAR: non-GAAP operating margin below 31% ex-refunds, backlog growth under 5%, or another quarter where two thirds of the growth is bought.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Constellation Energy Corporation (CEG) Q2 2026 — GAAP EPS $1.42, DOWN 47%. Adjusted operating earnings $2.55, UP 33.5% against a ~$2.36 bar. Revenue $7,504M, up 23%, but BELOW a ~$7.83B bar. FY2026 guidance RAISED to $11.50-$12.50. One non-cash line is $0.94 of the $1.13 gap.

Two earnings numbers in one filing, pointing opposite ways. GAAP EPS fell 47% to $1.42 while adjusted operating earnings - the basis Constellation guides on - ROSE 33.5% to $2.55. The $1.13 gap reconciles to the penny, and $0.94 of it is one non-cash line: unrealized marks on economic hedges, a $340M loss added back where a year ago the same line was a $121M GAIN. Our model says ~$285 vs $268.03.

THE CALL: HOLD (3/5, A BETTER BUSINESS, AND ONLY SIX PERCENT OF UPSIDE) — base-case value ~$285.0 vs ~$268.03 today.

KEY METRICS:

- THE CALL: HOLD 3/5, fair value ~$285 vs $268.03 (+6%) - not a margin of safety. Street: 20 analysts, 14 Buy / 6 Hold / 0 Sell, $355.20 average (low $296, high $441); we sit BELOW their lowest target. We take Constellation's own 2029 framework, $17.30/sh, at a 21x exit and a 9% discount rate = $285. Bull $360 = the Street's $19.99 at 23x, which lands on their own average - their target IS our bull case. Bear $179. To reach $355 you pay 26.2x the same 2029 number.

- THE PRINT: Adjusted operating earnings $2.55 vs $1.91, UP 33.5%, against a ~$2.36 bar - an ~8% beat against the HIGHEST published bar (others carried $2.28-$2.33). In dollars $920M vs $599M, UP 53.6%. GAAP EPS $1.42 vs $2.67, DOWN 47%; net income to shareholders $513M vs $839M. Revenue $7,504M, +23%, but BELOW a ~$7.83B bar. FY2026 guidance RAISED to $11.50-$12.50 from $11.00-$12.00 - both ends up $0.50, a $12.00 midpoint vs ~$11.63 modelled.

- THE $1.13 BRIDGE, TO THE PENNY: unrealized fair-value marks +$0.94 (a $340M after-tax LOSS on economic hedges, where a year ago the same line was a $121M GAIN - a $1.32/sh swing nobody earned or spent); acquired commodity-contract amortisation +$0.41 (Calpine purchase accounting, non-cash); Calpine merger/integration +$0.23 (real cash); legal/environmental +$0.10; pension +$0.06; decommissioning -$0.61. Over four trailing quarters GAAP is $10.26 and adjusted $10.63 - 3.6% apart.

- IT BEAT INTO ITS HEAVIEST MAINTENANCE QUARTER - ON CAPACITY PRICES. Nuclear output FELL to 44,160 GWh from 45,170; capacity factor 93.0% vs 94.8%; 86 planned refueling outage days vs 41, more than double (outages ran 40% faster than the 38-day industry average). The earnings came from PJM: Eastern Mid-Atlantic capacity $289.67/MW-day vs $125.71 (+130%), ComEd $289.67 vs $109.25 (+165%), PJM West power $51.40/MWh vs $42.43. Illinois ZEC prices collapsed $6.64 to $1.12.

- CAPITAL ALLOCATION IS THE CRITICISM; THE CONTRACTS ARE THE BULL CASE. Six-month operating cash flow $1,553M vs $2,521M capex = NEGATIVE $968M free cash flow, while $1,971M went to buybacks funded by $5,001M of new debt; cash fell $3,641M to $697M; goodwill $420M to $11,527M; shares 314M to 360M (+14.6%). Against that: ~920 MW of new 15-20yr nuclear PPAs (18.5yr avg, investment-grade, ~30% of baseload contracted by 2032), Crane cleared by FERC and the NRC for a 2027 restart, Ginna and Nine Mile Point 1 filed to 2049, and a $44.75/MWh PTC floor through 2032.

What to watch: UP: PJM capacity clearing near $290/MW-day again, Crane energised on schedule in 2027, or another gigawatt of long-term nuclear PPAs. BEAR: capacity back under $150/MW-day, a 2027 guide below $13.00, or another year of debt-funded buybacks while free cash flow stays negative.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.